Tag
Briefings and ideas about Dario Amodei from AI podcast discussions and the research they cite, with links to the original sources.
Alexander Wissner-Gross called Anthropic CEO Dario Amodei's plan for pacing frontier AI a "safety cartel" on Moonshots; Dave Blundin said labs may need antitrust permission to coordinate but agreed shared safety rules could shut out startups.
OpenAI has proposed ending Cursor's access to its models on 12 November, after SpaceX bought Cursor. On Moonshots, one panelist saw a bet on OpenAI's own enterprise stack; another argued the real prize is reasoning traces.
GenBio's AIDO Cell simulates a human cell that remembers successive edits and drugs. For now it helps prioritize experiments in two cell lines; lab validation of its novel predictions is underway. A Moonshots panelist called it the end of medicine.
Anthropic is reportedly weighing super-voting shares to keep founders in control after its IPO, per The Information. A Moonshots panel splits over who really steers a frontier AI lab: founders, its benefit trust or market pressure.
Moonshots panelists debated a relayed claim that 70% of China's AI token use goes to video: Alex Wissner-Gross said US labs chase revenue per token, and Dave Blundin that video sells where enterprises won't trust Chinese models.
Physicist Brian Greene argued with an AI on The Diary of a CEO that self-improving AI may approach a ceiling set by its architecture, not accelerate indefinitely—while warning that if no ceiling exists, gains could outpace human oversight.